ProAir
Total Payments
$1.1M
Transactions
324
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.1M | 324 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 324 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ABS-AS-30064 | Teva Pharmaceuticals USA, Inc. | $1.0M | 2 |
| ABS-COPD-30065 | Teva Pharmaceuticals USA, Inc. | $58,000 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 2
- Transactions 324
About ProAir
ProAir is a drug associated with $1.1M in payments to 2 healthcare providers, recorded across 324 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $1.1M was paid across 324 transactions to 2 doctors.
The most common payment nature for ProAir is "Unspecified" ($1.1M, 100.0% of total).
ProAir is associated with 2 research studies, including "ABS-AS-30064" ($1.0M).